News

Published on 29 May 2024 on Simply Wall St. via Yahoo Finance

These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat


Article preview image

The latest analyst coverage could presage a bad day for Merus N.V. (NASDAQ:MRUS), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. Bidders are definitely seeing a different story, with the stock price of US$54.87 reflecting a 26% rise in the past week. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.

Following the downgrade, the most recent consensus for Merus from its twelve analysts is for revenues of US$40m in 2024 which, if met, would be a modest 5.2% increase on its sales over the past 12 months. Per-share losses are expected to see a sharp uptick, reaching US$2.94. However, before this estimates update, the consensus had been expecting revenues of US$48m and US$2.84 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.

NASDAQ.MRUS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this...

Insider Monkey · via Yahoo Finance 17 Jan 2025

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In...

Insider Monkey · via Yahoo Finance 10 Dec 2024

Merus Scores Its First FDA Approval For Lung Cancer Drug

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the fi...

Benzinga · via AOL 6 Dec 2024

Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' - General Motors...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Merus N.V. MRUS is still “very, very specu...

Benzinga 5 Dec 2024

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab,...

Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on...

Benzinga · via AOL 3 Dec 2024

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab,...

Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on...

Benzinga · via Yahoo Finance 3 Dec 2024

XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday - Akso...

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Monday. Shares o...

Benzinga 2 Dec 2024

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In t...

Insider Monkey · via Yahoo Finance 23 Nov 2024

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this...

Insider Monkey · via Yahoo Finance 14 Nov 2024

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were...

Key Insights Significantly high institutional ownership implies Merus' stock price is sensitive t...

Simply Wall St. · via Yahoo Finance 21 Jul 2024